Tonix Pharmaceuticals Holding Corp. Stock

$34.89

1.83% yesterday

Nasdaq, Jun 27, 10:11 pm CET

ISIN

US8902604094

Symbol

TNXP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Tonix Pharmaceuticals Holding Corp. Stock price

$34.89

-398,941.11 99.99% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.65 1.83%

ISIN

US8902604094

Symbol

TNXP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$256.7m

Enterprise Value

$125.0m

Net debt

$-131.7m

Cash

$131.7m

Shares outstanding

6.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

25.57 | 22.77

EV/Sales

12.45 | 11.09

EV/FCF

negative

P/B

1.33

Financial Health

Equity Ratio

85.68%

Return on Equity

-93.18%

ROCE

-40.09%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$10.0m | $11.3m

EBITDA

$-69.7m | -

EBIT

$-72.4m

Net Income

$-131.9m | $-92.5m

Free Cash Flow

$-60.0m

Growth (TTM | estimate)

Revenue

-2.05% | 11.70%

EBITDA

31.10% | -

EBIT

31.54%

Net Income

-33.80% | 28.88%

Free Cash Flow

34.03%

Margin (TTM | estimate)

Gross

29.81%

EBITDA

-694.58% | -

EBIT

-721.51%

Net

-1,313.87% | -820.62%

Free Cash Flow

-597.02%

EPS

$-22.25

FCF per Share

$-8.71

Short interest

15.36%

Employees

81.00

Rev per Employee

$120.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	10 10	2% 2% 100%
- Direct Costs	7.05 7.05	10% 10% 70%
Gross Profit	2.99 2.99	22% 22% 30%
- Selling and Administrative Expenses	41 41	12% 12% 407%
- Research and Development Expense	35 35	53% 53% 344%
EBITDA	-70 -70	31% 31% -695%
- Depreciation and Amortization	2.70 2.70	41% 41% 27%
EBIT (Operating Income) EBIT	-72 -72	32% 32% -722%
Net Profit	-132 -132	34% 34% -1,314%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Tonix Pharmaceuticals Holding Corp. Stock News

Positive

Seeking Alpha

●

12 days ago

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

I'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved market; FDA decision is due August 15th, and approval could dramatically boost Tonix's revenue. Tonix has its work cut out for it, but I'm a firm believer that they could have a first-mover advantage ...

Neutral

GlobeNewsWire

●

12 days ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia: FDA PDUFA goal date of August 15, 2025 TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized placebo-controlled Phase 3 studies If approved by FDA, TNX-102 SL w...

Neutral

Seeking Alpha

●

15 days ago

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Tonix Pharmaceuticals' TNX-102 SL shows a high probability of FDA approval for fibromyalgia, supported by positive Phase 3 trials and an acceptable safety profile. A recent $500M shelf offering caused a stock dip but does not impact approval odds; current valuation does not include TNX-102 approval. Risks include modest efficacy and challenging market adoption; therefore, we recommend buying TN...

More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office	United States
CEO	Seth Lederman
Employees	81
Founded	2007
Website	www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now